Key result
Genetically predicted /dL higher Lp(a) linked to ~5% greater ischemic stroke risk.
Why the study?
Does a genetically predicted increase in Lp(a) levels increase the risk of cerebrovascular disease outcomes?
Observational (n=343,681)
Does a genetically predicted increase in Lp(a) levels increase the risk of cerebrovascular disease outcomes?
Answers are grounded in this paper and cite their sources.
Genetically predicted higher Lp(a) levels are strongly associated with ischemic stroke due to large artery atherosclerosis, supporting the targeting of Lp(a) in atherosclerotic stroke prevention.
Background: Lipoprotein(a) [Lp(a)] is a highly atherogenic lipoprotein and a target of investigational therapies. Using a Mendelian randomization (MR) study design, we aimed to clarify associations between genetically predicted Lp(a) levels and cerebrovascular disease outcomes and endophenotypes. Methods: We obtained genetic associations with Lp(a) levels ( n =343,681), ischemic stroke subtypes (≤62,100 cases), intracranial hemorrhage subtypes (≤15,400 cases), and twelve related cerebrovascular phenotypes. Lp(a) was proxied using two LPA genetic variants (rs10455872 and rs3798220) that explain 36% of the variance in Lp(a) levels. We performed MR analyses to estimate the association of a genetically predicted 50 mg/dL increase in Lp(a) levels on each outcome. Results: Genetically predicted Lp(a) levels associated with significantly increased risk of all-cause ischemic stroke (OR 1.05, 95% confidence interval [CI] 1.03-1.08, P =2.05x10 -4 ) and large artery atherosclerotic stroke (OR 1.26, 95% confidence interval [CI] 1.15-1.37, P =3.54x10 -7 ). There was a nominal association with cardioembolic stroke (OR 1.07, 95% CI 1.01-1.14, P =0.02), and no evidence for association with small vessel stroke (OR 0.98, 95% CI 0.90-1.06, P =0.60). Associations with early-onset stroke were similar, though with a greater magnitude of association for large artery atherosclerotic stroke (OR 1.42, 95% CI 1.16-1.72, P =5.58x10 -4 ). Secondary outcomes paralleled these findings, including significant associations with carotid plaque and atrial fibrillation, nominal associations with autopsy-confirmed microinfarcts, and null associations with small vessel disease markers. Although the association with intracerebral hemorrhage was null (OR 0.94, 95% CI 0.81-1.08, P =0.37), we found a nominal association with lobar hemorrhage (OR 1.90, 95% CI 1.00-3.61, P =0.05) and directionally concordant but nonsignificant associations with lobar microbleeds and autopsy-confirmed cerebral amyloid angiopathy. Conclusions: Lp(a) is strongly associated with ischemic stroke due to large artery atherosclerosis, supporting prioritization of patients with atherosclerotic disease in Lp(a)-lowering stroke prevention trials. Potential links to lobar hemorrhage and cerebral amyloid angiopathy warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Daghlas et al. (2026) conducted an observational in Cerebrovascular disease (n=343,681). Genetically predicted Lipoprotein(a) levels was evaluated on All-cause ischemic stroke (OR 1.05, 95% CI 1.03-1.08, p=2.05x10 -4). A genetically predicted /dL increase in Lipoprotein(a) levels was associated with an increased risk of all-cause ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: